A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Clinical trial NCT04928846 · RECRUITING

Trial details

NCT number: NCT04928846
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer

Start date: 2022-03-25
Primary completion: 2028-12-01
Enrollment: 768

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.